Alert: New Earnings Report (11/2/23)-Acadia Pharmaceuticals Inc (NASDAQ: ACAD).


For its third fiscal quarter (ending September 30), Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has reported E.P.S. of $-0.40 compared to $-0.17 a year ago. This performance was $0.02 better than the consensus estimate of $-0.42. E.P.S. were $-0.91 for the latest four quarters through September 30 versus $-1.35 for the same period a year ago.


Recent Price Action

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock rose modestly by 0.3% on 11/2/23. The stock closed at $22.99. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 1.8% during the last week.

Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to exceed the cost of capital, ACAD is expected to be a major Value Builder.

Acadia Pharmaceuticals has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Acadia Pharmaceuticals has a very low Appreciation Score of 8 but a very high Power Rating of 91, leading to the Neutral Value Trend Rating.

Rating Review

In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.

Be the first to comment

Leave a Reply

Your email address will not be published.